Drugs / rAd5 Env B
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01479296 | Dec 2011 → May 2013 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01095224 | Sep 2010 → Oct 2012 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rAd5 Env B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01095224 ↗ |
| Modality | Vaccine | “adenovirus-based HIV-1 vaccine regimen” NCT01095224 ↗ |
| Route | Intramuscular | “1 x 10\^10 PU administered as 1 mL IM in deltoid” NCT01095224 ↗ |